Key result
Physiological endotyping in INOCA identifies high-risk microvascular disease to guide outcome-improving targeted therapies.
Why the study?
Ischemia with non-obstructive coronary arteries (INOCA), driven largely by coronary microvascular dysfunction and vasospastic angina, is a widespread yet frequently overlooked clinical presentation.
Does physiological evaluation and endotype-specific targeted therapy improve clinical outcomes (MACE, HFpEF, persistent angina, and death) in patients with ischemia with non-obstructive coronary arteries (INOCA)?
Does physiological evaluation and endotype-specific targeted therapy improve clinical outcomes (MACE, HFpEF, persistent angina, and death) in patients with ischemia with non-obstructive coronary arteries (INOCA)?
INOCA is a non-benign condition where depressed CFR and elevated IMR predict higher rates of MACE, HFpEF, and death, underscoring the necessity of prompt physiological endotyping and targeted therapy.
Answers are grounded in this paper and cite their sources.
Supports physiology-guided INOCA management for risk stratification; leaves open whether endotype-targeted therapy reduces hard MACE in large-scale randomized trials.
Background: Chest pain without epicardial coronary obstruction termed ischemia with non-obstructive coronary arteries (INOCA) is a widespread yet frequently overlooked clinical presentation. Coronary microvascular dysfunction (CMD) and vasospastic angina (VSA) drive most cases, either individually or together. Methods: Searching PubMed, Scopus, and Web of Science for studies published between 2021and 2026, we analyzed key data on invasive functional testing, non-invasive imaging modalities, microvascular pathophysiology, and clinical risk profiles. Results: At the cellular level, CMD stems from diminished nitric oxide availability, structural vascular remodeling, heightened vascular tone, and impaired arteriolar dilation. VSA involves severe vasomotor reactivity, often occurring alongside CMD. Quantitative diagnostic metrics including coronary flow reserve (CFR), index of microvascular resistance (IMR), acetylcholine provocation, PET blood flow mapping, and stress perfusion CMR enable clear endotype categorization. Depressed CFR and elevated IMR directly portend higher rates of MACE, HFpEF, persistent angina, and death. Targeted therapies matched to specific endotypes improve patient outcomes, though large hard-endpoint trials remain underway. Conclusion: INOCA is not a benign condition. Prompt physiological evaluation and endotype-specific care are essential to optimize outcomes.
No takes yet. Share an insight, caveat, or question.
Ghaffar et al. (2026) conducted a review in Ischemia with non-obstructive coronary arteries (INOCA), including coronary microvascular dysfunction (CMD) and vasospastic angina (VSA). Physiological evaluation (CFR, IMR, acetylcholine provocation, PET, stress perfusion CMR) and endotype-specific targeted therapies was evaluated on Major adverse cardiovascular events (MACE), HFpEF, persistent angina, and death. Quantitative physiological diagnostics (CFR, IMR, PET, CMR) enable INOCA endotyping, where depressed CFR and elevated IMR portend higher major cardiovascular events and death, and targeted therapies improve outcomes.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: